Compounders Research Compare

Greenwich LifeSciences, Inc.(GLSI)

Biotechnology · Stafford, TX

$16.81-0.11 (-0.62%)

Delayed quote: Oct 6, 2026, 11:31 AM EDT

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.

Stafford, TX

13 employees

greenwichlifesciences.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Snehal S. Patel

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T15:33:05.353Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:33:05.353Z.

Quote observation: 2026-10-06T15:31:17.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 246,667,285
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 8,876,353
TTM operating income · period ending 2026-06-30: -21,867,032

FMP input reference: b6268879a98e6c39cef7c3f9e2e80a63ea5355fd191f52e510f01db01fc6dd59

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

GLSI EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

GLSI Competitors' EV/EBIT Ratio

Greenwich LifeSciences, Inc.

Current

Market Cap

$246.67M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Invivyd, Inc.

Market Cap

$248.06M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Nautilus Biotechnolgy, Inc.

Market Cap

$249.23M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Lifecore Biomedical, Inc.

Market Cap

$243.62M

EV/EBIT Ratio

N/A

TTM Avg

98.16x

3Y Avg

1055.07x

5Y Avg

378.93x

Galectin Therapeutics Inc.

Market Cap

$242.35M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Akebia Therapeutics, Inc.

Market Cap

$240.98M

EV/EBIT Ratio

N/A

TTM Avg

245.87x

3Y Avg

245.87x

5Y Avg

245.87x

InflaRx N.V.

Market Cap

$241.56M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CAMP4 Therapeutics Corporation

Market Cap

$240.97M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

High Tide Inc.

Market Cap

$237.69M

EV/EBIT Ratio

99.44x

TTM Avg

177.33x

3Y Avg

172.45x

5Y Avg

172.45x

BioAge Labs Inc.

Market Cap

$237.38M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Greenwich LifeSciences, Inc. (GLSI)	$246.67M	N/A	N/A	N/A	N/A
Invivyd, Inc. (IVVD)vs ›	$248.06M	N/A	N/A	N/A	N/A
Nautilus Biotechnolgy, Inc. (NAUT)vs ›	$249.23M	N/A	N/A	N/A	N/A
Lifecore Biomedical, Inc. (LFCR)vs ›	$243.62M	N/A	98.16x	1055.07x	378.93x
Galectin Therapeutics Inc. (GALT)vs ›	$242.35M	N/A	N/A	N/A	N/A
Akebia Therapeutics, Inc. (AKBA)vs ›	$240.98M	N/A	245.87x	245.87x	245.87x
InflaRx N.V. (IFRX)vs ›	$241.56M	N/A	N/A	N/A	N/A
CAMP4 Therapeutics Corporation (CAMP)vs ›	$240.97M	N/A	N/A	N/A	N/A
High Tide Inc. (HITI)vs ›	$237.69M	99.44x	177.33x	172.45x	172.45x
BioAge Labs Inc. (BIOA)vs ›	$237.38M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics